Predict your next investment

Asset/Investment Management
wisdomont.com

See what CB Insights has to offer

Investments

27

Portfolio Exits

1

About WisdoMont

WisdoMont is an equity investor that looks for opportunities in medical health and AI/big data fields, focusing on sustainable growth and development that can create the best value for its clients.

WisdoMont Headquarter Location

D-1004, Bund SOHO No.300 RenMin Rd, HuangPu District

Shanghai, Shanghai, 200002,

China

+86 021-58822309

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest WisdoMont News

Viva Biotech Partnership Summit Successfully Launched in Shanghai

Nov 15, 2019

Viva Biotech Partnership Summit Successfully Launched in Shanghai Distinguished guests including Qun Dang, Vice President of CSPC Pharma; Zhiping Cui, Assistant President of Fosun Group; Jia Zhu, Managing Director of Bain Capital; Shixiong Gan, Founder of WisdoMont; Yijing Xie, Managing Director of China Renaissance; Denise Chen, Managing Partner of GTJA Investment; John Zhu, Partner of 6 Dimensions Capital; Kevin Chen, Partner of BioTrack Capital; Dan Zhang, Chairman of Fountain Medical; and Guochun Li, Partner of YuanBio Venture Capital presented at the Summit. Innovation from 0 to 1 2019 is a vital and challenging year for healthcare industry and capital market, as well as a milestone year for Viva Biotech. Viva Biotech was successfully listed on Hong Kong Stock Exchange in May 2019. Its platform for incubation and innovative equity-for-service (EFS) model, VBI, was growing steadily. Dr. Cheny Mao, Chairman and CEO of Viva Biotech, said in the opening speech, "Biopharmaceutical is one of the most potential fields in China, where suits the best for the incubation of biotech startups. Relying on our strong drug discovery platform, Viva Biotech will provide services to more biotech startups with promising future and help realizing their great ideas." Other guests also shared their valuable thoughts regarding pharmaceutical innovation and investment environment, that other than those popular fields such as cancer, biotech startups should have more choices. Innovative drugs against different indications have various market demands and value, and differentiated innovation will draw more attention and gain favors from capital market. Cooperation Cultivates Growth At the Summit, Dr. David Xu, Chief Business Officer of Viva Biotech, introduced the positioning and model of VBI, "VBI is solely dedicated to the exploration, investment and service for valuable biopharmaceutical innovation concepts in various indication fields worldwide, and high potential startups with innovative solutions to unmet clinical needs. Viva Biotech strives to build up a 'one-stop' resources center and open platform for energetic biopharmaceutical startups and establish an ecosystem through wide cooperation with investors and industry participants, to create values for our platform companies, and therefore to achieve win-win situations for multiple parties." Most of the biopharmaceutical startups attending the Summit are from North America and China, whose product pipelines mainly focus on the unmet clinical needs in the market. Meanwhile, biopharmaceutical innovative enterprises are facing challenges such as high technical barriers, long innovation period, insufficient capital and long-term service support, thus powerful supports from both biopharmaceutical industry chains and capital markets are needed. Scientists, sizable pharmaceutical enterprises and capital market form complementary relationships with each other, hence cultivates the sustainable collaboration on biopharmaceutical innovation through their organic communication and mutual achievement. In the afternoon, senior management of domestic and overseas renowned investment institutions and pharmaceutical enterprises gathered to explore the forward-looking scientific researches in novel drugs, including innovative treatments for metabolic disorder, oncological diseases and CNS diseases. Nine enterprises including QureBio, Unibiotest, Arthrosi, Acura, ABM, Blue Oak, Saverna, VivaVision and Forkhead attended the pitch challenge sessions at the Summit. Media contact:

WisdoMont Investments

27 Investments

WisdoMont has made 27 investments. Their latest investment was in Concord Medical Cancer Center as part of their Unattributed - II on August 8, 2021.

CBI Logo

WisdoMont Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/24/2021

Unattributed - II

Concord Medical Cancer Center

$62.2M

Yes

Undisclosed Investors

1

5/10/2021

Private Equity

ETHealthcare

$100M

Yes

Hidragon Capital, Hillhouse Capital Management, Innovation Works, Kaiser Permanente, Legend Capital, Matrix Partners China, Qiming Venture Partners, Sequoia Capital China, and Sinovation Ventures

4

11/16/2020

Series B - II

Gene+ Technology

$37.97M

Yes

Aier Eye Hospital Group, HighLight Capital, Huagai Capital, and Sharewin Fund

7

7/8/2020

Series B - III

Subscribe to see more

$99M

Subscribe to see more

10

1/20/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/24/2021

5/10/2021

11/16/2020

7/8/2020

1/20/2020

Round

Unattributed - II

Private Equity

Series B - II

Series B - III

Series A

Company

Concord Medical Cancer Center

ETHealthcare

Gene+ Technology

Subscribe to see more

Subscribe to see more

Amount

$62.2M

$100M

$37.97M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Undisclosed Investors

Hidragon Capital, Hillhouse Capital Management, Innovation Works, Kaiser Permanente, Legend Capital, Matrix Partners China, Qiming Venture Partners, Sequoia Capital China, and Sinovation Ventures

Aier Eye Hospital Group, HighLight Capital, Huagai Capital, and Sharewin Fund

Sources

1

4

7

10

10

WisdoMont Portfolio Exits

1 Portfolio Exit

WisdoMont has 1 portfolio exit. Their latest portfolio exit was Sun-Novo Pharmaceutical on June 21, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/21/2021

IPO

$991

2

Date

6/21/2021

Exit

IPO

Companies

Valuation

$991

Acquirer

Sources

2

WisdoMont Team

1 Team Member

WisdoMont has 1 team member, including current Founding Partner, Shixiong Gan.

Name

Work History

Title

Status

Shixiong Gan

Founding Partner

Current

Name

Shixiong Gan

Work History

Title

Founding Partner

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.